Skip to main content

Advertisement

Fig. 7 | Journal of Biomedical Science

Fig. 7

From: Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors

Fig. 7

Combination therapy inhibits tumor growth of nasopharyngeal cancer in vivo. (a and b) Loss of NFBD1 signifcantly reduces xenograft growth after PARP inhibitor olaparib treatment. The tumors were measured every week using a digital caliper. Tumor volume = 1/2 × length × width2. (c) Tumor weight at 42 days after treatments, n = 6 mice per condition. *P < 0.05 and **P < 0.01

Back to article page